Journal article
Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
The Journal of nuclear medicine (1978), Vol.62(Suppl 3), pp.12S-22S
12/2021
DOI: 10.2967/jnumed.121.262750
PMCID: PMC12079724
PMID: 34857617
Abstract
Radiopharmaceutical therapy (RPT) is defined as the delivery of radioactive atoms to tumor-associated targets. In RPT, imaging is built into the mode of treatment since the radionuclides used in RPT often emit photons or can be imaged using a surrogate. Such imaging may be used to estimate tumor-absorbed dose. We examine and try to elucidate those factors that impact the absorbed dose-versus-response relationship for RPT agents. These include the role of inflammation- or immune-mediated effects, the significance of theranostic imaging, radiobiology, differences in dosimetry methods, pharmacokinetic differences across patients, and the impact of tumor hypoxia on response to RPT.
Details
- Title: Subtitle
- Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
- Creators
- George SgourosYuni K Dewaraja - University of MichiganFreddy Escorcia - National Cancer InstituteStephen A Graves - University of IowaThomas A Hope - University of California, San FranciscoAmir Iravani - MallinckrodtNeeta Pandit-Taskar - Memorial Sloan Kettering Cancer CenterBabak Saboury - National Institutes of HealthSara St James - University of California, San FranciscoPat B Zanzonico - Memorial Sloan Kettering Cancer Center
- Resource Type
- Journal article
- Publication Details
- The Journal of nuclear medicine (1978), Vol.62(Suppl 3), pp.12S-22S
- DOI
- 10.2967/jnumed.121.262750
- PMID
- 34857617
- PMCID
- PMC12079724
- NLM abbreviation
- J Nucl Med
- ISSN
- 0161-5505
- eISSN
- 1535-5667
- Grant note
- R01 EB022075 / NIBIB NIH HHS R01 CA240706 / NCI NIH HHS
- Language
- English
- Date published
- 12/2021
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Radiology; Radiation Oncology
- Record Identifier
- 9984383309702771
Metrics
11 Record Views